These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22542530)

  • 41. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
    Jones PH; Goldberg AC; Knapp HR; Kelly MT; Setze CM; Stolzenbach JC; Sleep DJ
    Am Heart J; 2010 Oct; 160(4):759-66. PubMed ID: 20934572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy.
    Konstandin MH; Blessing E; Doesch A; Ammon K; Koch A; Wabnitz GH; Gleissner CA; Remppis A; Katus HA; Dengler TJ
    Clin Transplant; 2008; 22(5):639-44. PubMed ID: 18492070
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
    Liska B; Khattab AA; Herrmann L; Abdel-Wahab M; Westphal R; Tölg R; Geist V; Richardt G
    Herz; 2008 Jul; 33(5):362-7. PubMed ID: 18773156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
    Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of cholesterol uptake inhibition added to statin therapy among subjects following a low-carbohydrate diet: a randomized controlled trial.
    Chirinos JA; Williams MM; Bregman DB; Ashfaq H; Khayyam U; Iqbal N
    Am Heart J; 2010 May; 159(5):918.e1-6. PubMed ID: 20435205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
    Negredo E; Moltó J; Puig J; Cinquegrana D; Bonjoch A; Pérez-Alvarez N; López-Blázquez R; Blanco A; Clotet B; Rey-Joly C
    AIDS; 2006 Nov; 20(17):2159-64. PubMed ID: 17086055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lower level of low-density lipoprotein cholesterol by statin prevents progression of coronary restenosis after successful stenting in acute myocardial infarction.
    Iwata A; Miura S; Shirai K; Kawamura A; Tomita S; Matsuo Y; Zhang B; Nishikawa H; Kumagai K; Matsuo K; Saku K
    Intern Med; 2006; 45(15):885-90. PubMed ID: 16946569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction.
    Walter DH; Fichtlscherer S; Britten MB; Auch-Schwelk W; Schächinger V; Zeiher AM
    Am J Cardiol; 2002 Jan; 89(1):1-6. PubMed ID: 11779513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial.
    Takase S; Matoba T; Nakashiro S; Mukai Y; Inoue S; Oi K; Higo T; Katsuki S; Takemoto M; Suematsu N; Eshima K; Miyata K; Yamamoto M; Usui M; Sadamatsu K; Satoh S; Kadokami T; Hironaga K; Ichi I; Todaka K; Kishimoto J; Egashira K; Sunagawa K
    Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):350-358. PubMed ID: 27932353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serial change and its determinants of residual plaque characteristics under sirolimus-eluting stent: a coronary angioscopic study.
    Kanai T; Hiro T; Takayama T; Watanabe Y; Fukamachi D; Kitano D; Kawano T; Hirayama A
    J Cardiol; 2012 Oct; 60(4):270-6. PubMed ID: 22819742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
    Florentin M; Kostapanos MS; Nakou ES; Elisaf M; Liberopoulos EN
    J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):274-82. PubMed ID: 19724023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation.
    Walter DH; Fichtlscherer S; Britten MB; Rosin P; Auch-Schwelk W; Schächinger V; Zeiher AM
    J Am Coll Cardiol; 2001 Dec; 38(7):2006-12. PubMed ID: 11738308
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy.
    Schmidt-Lucke C; Fichtlscherer S; Rössig L; Kämper U; Dimmeler S
    Atherosclerosis; 2010 Jul; 211(1):249-54. PubMed ID: 20211468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of Combined Lipid-Lowering Therapy on Low-Density Lipoprotein Cholesterol Variability and Cardiovascular Adverse Events in Patients with Acute Coronary Syndrome.
    Tan H; Liu L; Zheng Q; Zhang D; Liu Q; Cui D; Gao L; Wang Z; Wang WL; Liu J
    Adv Ther; 2021 Jun; 38(6):3389-3398. PubMed ID: 34018147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.